Clinical trial
A Study to Assess APO866 for the Treatment of Advanced Melanoma
NCT00432107 · Valerio Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00432107 |
|---|---|
| Title | A Study to Assess APO866 for the Treatment of Advanced Melanoma |
| Official title | A Multi-centre, Two-stage, Open Label Phase II Study to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Advanced Melanoma. |
| Lead sponsor | Valerio Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | APO866 |
| Enrollment | 25 |
| Start date | Jul 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Feb 7, 2007 |
| Last update posted | Sep 29, 2015 |
| Countries | Austria, France, Germany, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: